← All trials
NCT07153744
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2025
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2029
- First posted
- Sep 4, 2025
- Last posted
- Sep 4, 2025
- Enrollment
- 9588
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Hutchison Pharmaceuticals LimitedLead sponsor
- Capital Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- University of South ChinaCollaborator
- Wenzhou Medical UniversityCollaborator
- Wuxi People's HospitalCollaborator
- Capital Medical UniversityCollaborator
- Yueyang Central HospitalCollaborator
- Fudan UniversityCollaborator
- Fudan UniversityCollaborator
- Jiangsu UniversityCollaborator
- North China University of Science and Technology Affiliated HospitalCollaborator
- Central South UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Central South UniversityCollaborator
- Central South UniversityCollaborator
- Jiangxi Provincial People's HospitalCollaborator
- Soochow UniversityCollaborator
- Xuancheng people's hospitalCollaborator
- Nanyang Medical CollegeCollaborator
- Shanghai UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Zhoukou Central HospitalCollaborator
- Huai'an First People's HospitalCollaborator
- Shanxi cardiovascular hospitalCollaborator
- Hebei UniversityCollaborator
- ZhuZhou Central HospitalCollaborator
- Changzhi Medical CollegeCollaborator
- Civil Aviation General HospitalCollaborator
- Fujian Medical UniversityCollaborator
- Jining NO.1 People 's HospitalCollaborator
- Fujian Medical UniversityCollaborator
- Weihai Municipal HospitalCollaborator
- LanZhou UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Guangdong Pharmaceutical UniversityCollaborator
- Weifang People's HospitalCollaborator
- Huazhong University of Science and TechnologyCollaborator
- First People's Hospital of ChenzhouCollaborator
- People's Hospital of QuzhouCollaborator
- Henan Medical UniversityCollaborator
- The First People's Hospital of LianyungangCollaborator
- Jingzhou Central HospitalCollaborator
- Peking UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- Anhui Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Ningxia Medical UniversityCollaborator
- Linyi People's HospitalCollaborator
- Shandong Province Qianfoshan HospitalCollaborator
- Cangzhou Central HospitalCollaborator
- Jinhua Central HospitalCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Nanchang UniversityCollaborator
- People's Hospital of RizhaoCollaborator
- Henan University of Traditional Chinese MedicineCollaborator
- People's Hospital of ChongqingCollaborator
- Wuhan UniversityCollaborator
- Qingdao UniversityCollaborator
- Hainan Medical CollegeCollaborator
- Tianjin Medical UniversityCollaborator
- Ningbo UniversityCollaborator
- Handan Central HospitalCollaborator
- Shanghai University of Traditional Chinese MedicineCollaborator
- Southwest Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- The First People's Hospital of Changde CityCollaborator
- Sichuan UniversityCollaborator
- Shandong University of Traditional Chinese MedicineCollaborator
- Ankang City Central HospitalCollaborator
- LinFen People's HospitalCollaborator
- Shijiazhuang People's HospitalCollaborator
- Taizhou Enze Medical Center GroupCollaborator
- Tongling People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.